Added to YB: 2025-09-18
Pitch date: 2025-09-16
HROW [bullish]
Harrow, Inc.
-22.38%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States.
Market Cap
$1.4B
Pitch Price
$42.90
Price Target
66.30 (+96%)
Dividend
N/A
EV/EBITDA
30.43
P/E
-260.02
EV/Sales
5.62
Sector
Pharmaceuticals
Category
growth
Show full summary:
HARROW Inc. ($HROW): Debt Refinancing Unlocks New Era of Growth
HROW: Debt refinanced $250M 2030 bonds replacing 2026/27 maturities, de-risking balance sheet. Q2 2025 GAAP profitable $5M, revenue +30% YOY to $63.7M. VEVYE prescriptions +66% sequentially, IHEEZO expected >$50M 2025 sales. PT $66.3 vs $42.8 current (+55% upside).
Read full article (8 min)